ProFound Therapeutics and Quotient Therapeutics have entered into separate feasibility agreements with GSK to discover and validate novel targets and therapeutic approaches in respiratory and liver diseases—marking the first company-focused agreements signed under the framework collaboration between Flagship and GSK to combine GSK’s disease area expertise and development capabilities with Flagship’s ecosystem of bioplatform companies, inclusive of its novel modalities and technologie...